Anika Therapeutics, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Anika Therapeutics, Inc. (ANIK) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.24 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-07-29
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was $0.24.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$0.37.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was -$0.22.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$0.33.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$0.70.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$0.60.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$0.23, a 253.33% decline from fiscal 2022.
- Anika Therapeutics, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was $0.15.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.24 10-Q · filed 2026-07-29 | -$0.13 10-Q · filed 2026-07-29 | ||
| 2026-03-31 | -$0.37 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | -$0.70 10-K · filed 2026-03-03 | |||
| 2025-09-30 | -$0.22 10-Q · filed 2025-11-05 | -$0.82 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | -$0.33 10-Q · filed 2026-07-29 | -$0.60 10-Q · filed 2026-07-29 | ||
| 2025-03-31 | -$0.28 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | -$0.60 10-K · filed 2026-03-03 | |||
| 2024-09-30 | -$0.12 10-Q · filed 2025-11-05 | -$0.43 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | -$0.17 10-Q · filed 2025-07-30 | -$0.30 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | -$0.13 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$0.23 10-K · filed 2026-03-03 | |||
| 2022-12-31 | $0.15 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |